今年以来，A股市场迎来16只新股上市，其中医疗器械企业占据四席，成为开年新股市场的亮点之一。 北京商报记者统计发现，年内上市的医疗器械企业包括科创板"新秀"北芯生命，以及北交所的海圣医 疗、爱得科技、爱舍伦，4只个股上市首日涨幅均超170%，展现出资本市场对医疗器械赛道的高度认 可。 股价亮眼的背后，是业绩基本面的支撑。作为以科创板第五套上市标准上市的企业，北芯生命预计去年 扭亏，另外3只北交所个股在去年的业绩均实现增长。目前，医疗器械企业上市"后备军"充足，其中人 工心脏领域的两家企业苏州同心医疗科技股份有限公司（以下简称"同心医疗"）和深圳核心医疗科技股 份有限公司（以下简称"核心医疗"）正共同冲刺"国产人工心脏第一股"。 上市首日表现亮眼 从市场表现看，北芯生命、海圣医疗、爱得科技、爱舍伦4只医疗器械新股可谓"开门红"。 交易行情显示，2月5日登陆科创板的北芯生命表现最为抢眼，上市首日收涨183.33%。盘中涨幅一度超 200%，全天成交金额达14.09亿元，总市值一度超过200亿元。作为医疗器械领域最新上市的新股，海 圣医疗于2月12日登陆北交所，上市首日大幅收涨172.86%。此外，爱得科技、爱舍伦 ...

招股书显示，核心医疗是一家致力于提供更全面、更创新、更优质的人工心脏产品的创新医疗器械企 业。公司自成立以来，聚焦急、慢性心衰重大临床需求，依托原始创新与关键核心技术攻关，持续推动 人工心脏领域产品迭代升级。 在首轮问询中，关于植入式、介入式人工心脏临床价值和竞争力，商业化进展以及市场空间等问题遭到 追问。 北京商报讯（记者 丁宁）2月2日晚间，上交所官网显示，深圳核心医疗科技股份有限公司（以下简 称"核心医疗"）科创板IPO已披露首轮审核问询函回复。 ...

据介绍，"人工心脏"即左心辅助装置，是一种尖端生命支持系统。整个装置系统分为体内和体外两部 分，体内的血泵和管道与心脏精密连接，体外的控制器和电池组让患者能够自由活动。此次接受"人工 心脏"植入的患者患有扩张型心肌病，其左室射血分数（LVEF）仅为15%，远低于55%的正常标准。该 疾病是一种遗传性疾病，目前尚无根治方案，随着病情进展，患者心脏功能逐年衰退。 合肥京东方医院心脏中心团队经过全面评估与审慎研讨，迅速组建由心脏外科、心血管内科、麻醉科、 体外循环科、重症监护室、超声科等多领域专家构成的诊疗团队。术中，团队默契配合、精准操作，成 功将"人工心脏"植入患者体内。装置启动后运行平稳，即刻承担起左心室泵血功能，患者全身血液循环 得到显著改善。 姚建民介绍，"人工心脏"是救治终末期心衰的关键手段，与心脏移植相比，术后不用终身服用抗排异 药。此外，该技术也为稀有血型、体重较大或65岁以上等难以接受心脏移植的患者，提供了新的治疗希 望。 近日，又一例"人工心脏"植入手术在合肥京东方医院成功开展。合肥京东方医院心胸外科主任姚建民表 示，植入的"人工心脏"仅90克，是由新型材料制成的一个很轻很小的机械装置。它协助心 ...

Group 1 - The recent surge in IPO applications in the Shanghai, Shenzhen, and Beijing stock exchanges is noted, with 29 companies receiving acceptance from December 25 to December 29, including 9 from the Beijing Stock Exchange and 9 from the ChiNext [1] - Among the accepted IPOs, several companies that previously failed to go public, such as Gaokai Technology, are making another attempt, with Gaokai aiming to raise approximately 1.5 billion yuan for semiconductor equipment development [1] - Two banks, Dongguan Bank and Nanhai Rural Commercial Bank, have resumed their IPO processes after being halted due to outdated financial documents, with Dongguan Bank having submitted its IPO application over 17 years ago [2] Group 2 - The current batch of accepted IPOs includes unprofitable companies, such as Xinnowei, which has accumulated losses of 1.65 billion yuan over the past three and a half years and plans to raise 2.94 billion yuan [2] - The increase in IPO applications at the end of the year is attributed to the financial report updates, as companies aim to submit their applications before the six-month validity period of their financial statements expires [3] - Looking ahead to 2026, the A-share market is expected to see steady growth in both the number of issuances and financing amounts, particularly for companies in priority development sectors such as AI, new energy, and high-end manufacturing [3]

Core Viewpoint - The ongoing debate in the academic community regarding the definition and standards of artificial heart technologies is crucial for patient safety and clinical outcomes [2][3][8]. Group 1: Technical Definitions and Standards - The definition of "full magnetic suspension" in contemporary durable rotary blood pumps is ambiguous, leading to potential misinterpretations of product safety [2][4]. - Experts emphasize that any blood pump relying on fluid dynamic bearings in its primary operating mode cannot be classified as "full magnetic suspension" [2][8]. - A recent paper by Dr. Kurt Dasse highlights the need for clear definitions and evaluation standards for different bearing technologies in artificial hearts [3][8]. Group 2: Key Characteristics of CorHeart 6 - The CorHeart 6 device is categorized as a "centrifugal pump with magnetic-assisted dual fluid dynamic bearings" in authoritative literature, yet its manufacturer describes it as a "full magnetic suspension device" [4][24]. - Key specifications of the CorHeart 6 include a rotor speed range of 2200-4300 RPM, a device height of 26 mm, a diameter of 34 mm, a weight of 90 g, and a power consumption of 2.6 W at 2.0 L/min [5][24]. Group 3: Consensus on Magnetic Suspension - Experts at the ISMCS conference reached a consensus that true magnetic suspension must rely solely on magnetic forces for rotor stability across multiple degrees of freedom [14][20]. - The safety threshold for suspension gaps is established at ≥200 microns for full magnetic suspension, contrasting with ≤100 microns for fluid dynamic bearings [20][24]. - Stability verification methods, such as air testing, are proposed to ensure that magnetic bearings can maintain rotor suspension without fluid assistance [23][24]. Group 4: Clinical Implications and Data Transparency - The distinction between bearing technologies is critical as it directly impacts blood compatibility and patient outcomes, with fluid dynamic bearings showing significantly higher mortality risks compared to full magnetic suspension devices [24][25]. - The lack of long-term clinical data and transparency in the CorHeart 6's public disclosures raises concerns about its safety and efficacy [24][25]. - The industry is urged to adopt standardized definitions and transparent data sharing to enhance patient safety and foster innovation [24][25].

Group 1: Core Insights - Brain science has emerged as a strategic high ground in global technological competition, driving advancements in the diagnosis and treatment of major brain diseases like Alzheimer's and supporting breakthroughs in brain-machine interface technologies [2][6][8] - Countries are increasingly incorporating brain science into national technology strategies, with significant initiatives such as the U.S. "BRAIN Initiative," the EU's "Human Brain Project," and China's "Brain Science and Brain-like Research" major project, reflecting a robust investment in research and infrastructure [2][7][8] - The global focus on brain science and brain-like intelligence is expected to continue growing, positioning these fields as key areas for future industrial development and international technological competition [8][9] Group 2: Market Performance - In the pharmaceutical sector, the medical services and traditional Chinese medicine II sub-industries recorded positive returns, with the pharmaceutical commercial sector leading at +5.19% [9][11] - The biopharmaceutical sector's valuation levels showed significant variation, with the highest being for biopharmaceuticals at 87.91 times earnings, while the lowest was for pharmaceutical commerce at 21.61 times [9][12] Group 3: Industry Trends - The recent international conference on artificial hearts highlighted the need for standardized definitions and terminology in the field, with significant participation from Chinese enterprises, indicating a collaborative effort to advance technology and improve clinical evaluations [14][15] - Shanghai is accelerating the development of brain-machine interface technologies, achieving milestones such as the first clinical trials for invasive brain-machine interfaces and the application of non-invasive products in rehabilitation and mental health [17][18]

Core Viewpoint - The 31st International Society for Mechanical Circulatory Support (ISMCS) annual meeting in Vienna focused on advancements in rotary blood pumps and related mechanical circulatory support systems, emphasizing the need for standardized terminology and definitions in the industry [1][3]. Group 1: Industry Developments - The meeting featured experts from multiple countries discussing the core topic of "Understanding Bearing Technologies in Contemporary Durable Rotary Blood Pumps," aiming to clarify concepts and unify terminology in artificial heart bearing technology [3][4]. - Heart failure, often referred to as the "cancer" of the cardiovascular field, affects over 60 million people globally, with a 50% five-year mortality rate upon diagnosis, comparable to that of malignant tumors [3][4]. Group 2: Challenges and Solutions - The lack of standardized terminology and clear definitions has hindered effective communication among industry experts, researchers, and clinicians, impacting the accurate understanding and evaluation of product performance [4]. - The conference underscored the importance of establishing a unified and scientific classification framework for bearing technologies, which could serve as a basis for future industry white papers and regulatory assessments [4][5]. Group 3: Key Contributions - Dr. Marvin Slepian, former president of the American Society for Artificial Internal Organs (ASAIO) and ISMCS, highlighted the need for clear technical definitions and industry consensus to promote healthy industry development [5]. - Dr. Chen Chen from Suzhou Tongxin Medical presented on the stability of magnetic and hydrodynamic bearings in blood pumps, emphasizing the critical relationship between bearing stability and blood damage, using the BrioVAD as a case study [5].

Core Insights - The field of xenotransplantation has made significant advancements in 2025, achieving breakthroughs that surpass the last century's progress [1] - A genetically edited pig kidney was successfully transplanted into a patient, Tim Andrews, who survived for 271 days, setting a new record for pig kidney transplants [1][2] - The comparison with a historical case from 1964 shows only a marginal improvement in survival time for xenotransplantation over 60 years [2] Group 1: Historical Context and Comparisons - The previous record for xenotransplantation was held by a female teacher who survived 269 days after receiving a chimpanzee kidney [2][3] - The advancements in genetic editing and immunosuppressive therapies have contributed to the increased survival time of xenotransplant patients [2][3] Group 2: Challenges and Limitations - Current challenges in xenotransplantation include immune rejection, infection risks, and biological compatibility issues [6][7] - The use of genetically modified pigs is preferred over primates due to ethical concerns, biological safety risks, and practical breeding considerations [5][6] Group 3: Technological and Regulatory Hurdles - Gene editing techniques have limitations, including the potential for new antigen production and the complexity of determining effective gene combinations [8][9] - Immunosuppressive drugs currently used are not specifically designed for xenotransplantation, leading to complications such as infections and organ toxicity [11][12] Group 4: Future Prospects and Comparisons with Artificial Organs - The development of artificial organs, particularly artificial hearts, is progressing rapidly, with several products nearing market readiness [13][15] - In contrast, the development of artificial kidneys and livers faces significant challenges, making them less competitive with xenotransplantation at this stage [16][17] Group 5: Expert Opinions and Future Directions - Experts believe that achieving a one-year functional survival for xenotransplanted organs could lead to broader acceptance and further advancements in the field [18]

Core Insights - The article discusses the recent acceptance of Core Medical's IPO application by the Shanghai Stock Exchange, with Hillhouse Capital and Zhengxin Valley recognized as qualified professional institutional investors [1][3] - This marks the second company to be recognized as a qualified professional institutional investor on the Sci-Tech Innovation Board, following Tainuo Maibo, which also involved Hillhouse [2][4] Company Overview - Core Medical, founded by a Harbin Institute of Technology PhD, has developed the world's smallest and lightest artificial heart, and its IPO application was accepted on November 6 [3] - Tainuo Maibo, established in 2015, is an innovative biopharmaceutical company that became the first to be accepted under the fifth listing standard of the Sci-Tech Innovation Board [4] Investment Landscape - Both companies are in the early commercialization stage of their products, resulting in low revenue and no profitability, aligning with the fifth listing standard that does not require revenue [4] - Hillhouse Capital has a long-standing relationship with both companies, holding 3.94% of Tainuo Maibo and 9.3% of Core Medical prior to their IPO applications [5] Institutional Investor Role - The introduction of qualified professional institutional investors is seen as a new pathway for leading institutions to participate in IPOs on the Sci-Tech Innovation Board [7] - Qualified institutional investors must meet high standards, including a proven track record of successful investments and a minimum investment threshold [8] Market Implications - The presence of qualified professional institutional investors is viewed as a positive indicator for potential investors, suggesting market wisdom and credibility [10] - However, for aspiring qualified institutional investors, the challenge lies in accurately assessing a company's potential for successful IPO [11]

Core Viewpoint - The pursuit of "health and longevity" is becoming a central goal in modern society, moving beyond mere longevity to maintaining quality of life over an extended lifespan. This shift is supported by a collaborative ecosystem of scientists, pharmaceutical and medical device companies, healthcare providers, and health service payers, driving the "big health" industry forward [1][2][7]. Group 1: Overview of the Big Health Industry - Well Equity Partners focuses on the health and longevity sector, backed by Walgreens Boots Alliance, a long-standing member of the Fortune Global 500 list [2]. - The collaboration between Fortune magazine and Well Equity Partners has identified 23 noteworthy companies in the big health sector, showcasing both established giants and emerging startups [2][3]. - The selected companies share a common trait: their business strategies and core operations align with the goals of promoting health and longevity [3][7]. Group 2: Key Companies in the Big Health Sector - Notable companies include UnitedHealth Group, Elevance Health, Johnson & Johnson, Roche, HCA Healthcare, Bayer, Eli Lilly, Novo Nordisk, China National Pharmaceutical Group, and others, all of which are recognized in the Fortune Global 500 [5][6]. - Emerging companies such as Shanghai Ladder Medical Technology and Quantum Life Limited are also highlighted for their innovative contributions to the health and longevity landscape [6][7]. Group 3: Innovations in Disease Management - The focus on transforming severe diseases into manageable chronic conditions is crucial for achieving health and longevity. Companies are innovating in drug development and medical devices to address high-prevalence diseases like metabolic and neurodegenerative disorders [14][24]. - Novo Nordisk and Eli Lilly are leading in the diabetes treatment space with their GLP-1 drugs, which have opened new avenues for managing metabolic diseases [16][17]. - Bayer is pioneering cell and gene therapies for neurodegenerative diseases, particularly Parkinson's disease, showcasing advancements in treatment methodologies [19][20]. Group 4: Preventive Health and Early Diagnosis - The emphasis on early detection and diagnosis is vital for intercepting health issues before they escalate. Companies are developing portable and efficient diagnostic tools to enhance accessibility and accuracy in healthcare [26][27]. - Innovations in functional foods and lifestyle management are gaining traction, aligning with the "Food as Medicine" philosophy to prevent diseases through dietary interventions [31][32]. Group 5: Health Services and Insurance Models - Companies like UnitedHealth Group and Elevance Health are creating integrated ecosystems that encompass health insurance, medical services, and health information technology, optimizing patient care and cost efficiency [39][40]. - In China, Taikang Insurance Group is building a comprehensive health ecosystem that connects insurance, asset management, and healthcare services, addressing the needs of various demographics [40]. Group 6: Future Directions and Ecosystem Development - The evolution of the health and longevity sector is marked by a shift towards a more integrated approach, where scientific research, innovative products, and supportive payment mechanisms converge to enhance public health outcomes [44][46]. - The ongoing development of technologies and services aims to make health and longevity accessible to a broader population, moving from niche offerings to mainstream solutions [43][46].